Evidence map›Paper›PMID 35635006›Full record

ArticleMolecular pharmaceutics2022

"Human and Mouse Cross-Reactive" Albumin-Binding Helix-Loop-Helix Peptide Tag for Prolonged Bioactivity of Therapeutic Proteins.

Yuto Nakatani, Zhengmao Ye, Yuki Ishizue, Taishi Higashi, Teruko Imai, Ikuo Fujii, Masataka Michigami

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular pharmaceutics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.9field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 6 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Yuto NakataniDepartment of Biological Science, Graduate School of Science, Osaka Prefecture University, 1-1 Gakuen-cho, Naka-ku, Sakai, Osaka 599-8531, Japan.
Zhengmao YeInterprotein Corporation, 3-10-2 Toyosaki, Kita-ku, Osaka 531-0072, Japan.
Yuki IshizueGraduate School of Pharmaceutical Science, Kumamoto University, 5-1 Oe-Honmachi, Kumamoto 862-0973, Japan.
Taishi HigashiGraduate School of Pharmaceutical Science, Kumamoto University, 5-1 Oe-Honmachi, Kumamoto 862-0973, Japan.ORCID 0000-0001-8439-5377
Teruko ImaiGraduate School of Pharmaceutical Science, Kumamoto University, 5-1 Oe-Honmachi, Kumamoto 862-0973, Japan.
Ikuo FujiiDepartment of Biological Science, Graduate School of Science, Osaka Prefecture University, 1-1 Gakuen-cho, Naka-ku, Sakai, Osaka 599-8531, Japan.ORCID 0000-0003-2571-546X
Masataka MichigamiDepartment of Biological Science, Graduate School of Science, Osaka Prefecture University, 1-1 Gakuen-cho, Naka-ku, Sakai, Osaka 599-8531, Japan.ORCID 0000-0001-7075-8958
Osaka Prefecture University · JPKumamoto University · JPDaiichi University of Pharmacy · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The effectiveness of protein and peptide pharmaceuticals depends essentially on their intrinsic pharmacokinetics. Small-sized pharmaceuticals in particular often suffer from short serum half-lives due to rapid renal clearance. To improve the pharmacokinetics by association with serum albumin (SA)

Indexed as

PeptidesSerum Albumin, HumanAnimalsHalf-LifeHumansMiceSaccharomyces cerevisiaeSerum AlbuminPeptidesSerum AlbuminSerum Albumin, HumanCuAAChelix−loop−helixinsulinserum albuminyeast surface display

Identifiers

PMID35635006
PMCPMC9257745
OpenAlexW4281751414

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.